In a large, prospective cohort of women, those with LDL-c <70 mg/dL and potentially those with LDL-c ≥160 mg/dL and those with low TG, showed a higher risk of hemorrhagic stroke.
Among US adults, higher consumption of dietary cholesterol or eggs was significantly associated with higher risk of incident CVD and all-cause mortality in a dose-response manner.
In the CABANA trial, catheter ablation did not result in a reduction of death, disabling stroke, serious bleeding or cardiac arrest in symptomatic AF patients compared to drug therapy.
In an exploratory analysis of insurance data, DOAC use reduced stroke or systemic embolism in patients with mitral stenosis and AF compared to warfarin.
An Asian cohort of adults with non-valvular AF and low or very low body weight (<60/50 kg), showed better effectiveness and safety with regular and reduced DOAC dose, compared with warfarin.
Self-reported consumption of ≥2 artificially sweetened beverages per day was associated with higher risk of CV events, and all-cause mortality in postmenopausal women, as shown in an observational study.
This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.
Albiglutide was superior to placebo with respect to MACE in T2DM patients in the Harmony Outcomes trial without differences in serious adverse events.
In the ORBIT-AF multicenter cohort study, AF patients with cognitive impairment or frailty showed higher stroke risk and mortality, but OACs were underprescribed. The conditions did not affect OAC treatment effect.
A meta-analysis of 28 large RCTs including more than 14.000 individuals aged >75 years showed that the use of statins resulted in significant reductions of major vascular events regardless of age.
Low-dose rivaroxaban plus aspirin reduced the risk for stroke in patients with CAD or PAD, especially in those with prior stroke, as shown in a subanalysis of the COMPASS trial.
A meta-analysis of 13 randomized controlled trials showed that a loading dose of atorvastatin before PCI markedly reduced MACE in patients with ACS.